Spero Therapeutics Stock In The News

SPRO Stock  USD 0.78  0.03  4.00%   
Our overall analysis of Spero Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Spero Therapeutics. The specific impact of Spero Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Spero Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Spero Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Spero Therapeutics Backtesting and Spero Therapeutics Hype Analysis.
To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.

Spero Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
https://www.globenewswire.com/news-release/2025/02/25/3032206/0/en/UPDATE-Spero-Therapeutics-to-Present-at-TD-Cowen-45th-Annual-Health-Care-Conference.html
 Bullish
Yahoo News
14 Cheap Penny Stocks to Buy According to Analysts
https://finance.yahoo.com/news/14-cheap-penny-stocks-buy-155247615.html
 Bullish
Yahoo News
15 Cash-Rich Penny Stocks Hedge Funds Are Buying
https://finance.yahoo.com/news/15-cash-rich-penny-stocks-090736205.html
 Bullish
Yahoo News
11 Hyper-Growth Stocks Billionaires Are Loading Up On
https://finance.yahoo.com/news/11-hyper-growth-stocks-billionaires-094017302.html
 Bullish
Yahoo News
Spero Therapeutics, Inc. (NASDAQ:SPRO): Are Analysts Optimistic?
https://finance.yahoo.com/news/spero-therapeutics-inc-nasdaq-spro-132045392.html
 Bullish
Yahoo News
Spero Therapeutics Provides Corporate Update and 2024 Outlook
https://finance.yahoo.com/news/spero-therapeutics-provides-corporate-2024-130500258.html
 Bullish
Yahoo News
Spero Therapeutics Announces First Patie...
https://finance.yahoo.com/news/spero-therapeutics-announces-first-patient-130500863.html
 Bullish
Macroaxis News: globenewswire.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP...
https://www.globenewswire.com/news-release/2023/11/21/2784485/3080/en/SHAREHOLDER-ALERT-Levi-Korsinsky-LLP-Notifies-Shareholders-of-an-Investigation-Concerning-Possible-Breaches-of-Fiduciary-Duty-by-Certain-Officers-and-Directors-of-Spero-Therapeutic.html
 Neutral
Yahoo News
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript
https://finance.yahoo.com/news/spero-therapeutics-inc-nasdaq-spro-140256256.html
 Bullish
Macroaxis News: globenewswire.com
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
https://www.globenewswire.com/news-release/2023/11/13/2779452/0/en/Spero-Therapeutics-Announces-Third-Quarter-2023-Operating-Results-and-Provides-a-Business-Update.html
 Bullish

Spero Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Spero and other traded companies coverage with news coverage. We help investors stay connected with Spero headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Spero Stock performance. Please note that trading solely based on the Spero Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Spero Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Spero Therapeutics investors visualize upcoming and past events in order to time the market based on Spero Therapeutics noise-free hype analysis.
Spero Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Spero earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Spero Therapeutics that are available to investors today. That information is available publicly through Spero media outlets and privately through word of mouth or via Spero internal channels. However, regardless of the origin, that massive amount of Spero data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Spero Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Spero Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Spero Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Spero Therapeutics alpha.

Spero Largest EPS Surprises

Earnings surprises can significantly impact Spero Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-11-14
2022-09-30-0.3-0.33-0.0310 
2024-08-05
2024-06-30-0.38-0.330.0513 
2023-11-13
2023-09-30-0.030.040.07233 
2023-05-11
2023-03-31-0.33-0.250.0824 
2018-08-09
2018-06-30-0.77-0.690.0810 
2019-08-08
2019-06-30-0.65-0.74-0.0913 
View All Earnings Estimates

Spero Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Spero Therapeutics Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
zacks News
3rd of March 2025
Mersana Therapeutics, Inc. Reports Q4 Loss, Tops Revenue Estimates
at zacks.com 
zacks News
27th of February 2025
Acquisition by Tregoning Kathleen of 30943 shares of Spero Therapeutics at 1.29 subject to...
at zacks.com 
Gurufocus Stories at Macroaxis
25th of February 2025
UPDATE -- Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
at gurufocus.com 
Simply Wall St News at Macroaxis
4th of February 2025
Spero Therapeutics, Inc. Looks Inexpensive After Falling 27 percent But Perhaps Not Attrac...
at simplywall.st 
Gurufocus Stories at Macroaxis
10th of January 2025
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
at gurufocus.com 
zacks News
3rd of January 2025
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
at zacks.com 
zacks News
20th of December 2024
MRKs Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals
at zacks.com 
zacks News
18th of December 2024
REGNs Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
at zacks.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Spero Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Spero Therapeutics' short interest history, or implied volatility extrapolated from Spero Therapeutics options trading.
When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:
Check out Spero Therapeutics Backtesting and Spero Therapeutics Hype Analysis.
To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.753
Earnings Share
0.08
Revenue Per Share
1.984
Quarterly Revenue Growth
(0.47)
Return On Assets
(0.01)
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.